No headlines found.
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
Globe Newswire (Wed, 26-Feb 8:00 AM ET)
Globe Newswire (Tue, 25-Feb 8:00 AM ET)
Globe Newswire (Thu, 20-Feb 8:00 AM ET)
ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports
Globe Newswire (Tue, 18-Feb 8:00 AM ET)
Globe Newswire (Wed, 22-Jan 8:00 AM ET)
Globe Newswire (Wed, 11-Dec 8:00 AM ET)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Prophase Labs trades on the NASDAQ stock market under the symbol PRPH.
As of March 3, 2025, PRPH stock price declined to $0.40 with 1,748,358 million shares trading.
PRPH has a beta of -2.13, meaning it tends to be less sensitive to market movements. PRPH has a correlation of 0.03 to the broad based SPY ETF.
PRPH has a market cap of $12.09 million. This is considered a Sub-Micro Cap stock.
Last quarter Prophase Labs reported $3 million in Revenue and -$.35 earnings per share. This fell short of revenue expectation by $-21 million and missed earnings estimates by -$.39.
In the last 3 years, PRPH traded as high as $15.25 and as low as $.22.
The top ETF exchange traded funds that PRPH belongs to (by Net Assets): VTI, VXF, IWC.
PRPH has underperformed the market in the last year with a return of -91.6%, while the SPY ETF gained +16.8%. In the last 3 month period, PRPH fell short of the market, returning -48.1%, while SPY returned -2.1%. However, in the most recent 2 weeks PRPH has outperformed the stock market by returning +23.1%, while SPY returned -4.2%.
PRPH support price is $.38 and resistance is $.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRPH shares will trade within this expected range on the day.